Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1

References

• Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297–1302.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. JCO. 2003;21(24):4524–4531.
   PubMed Web of Science ®Google Scholar
• Abraham JE, Hiller L, Dorling L, et al. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Med. 2015;13(1):306.
   PubMedGoogle Scholar
• Banerji U, Ashley S, Coward J, et al. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer. 2006;54(3):371–377.
   PubMed Web of Science ®Google Scholar
• Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer. 2003;89(10):1837–1842.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Y, Shi Y, et al. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients. BMC Cancer. 2017;17(1):242.
   PubMedGoogle Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6(9):669–677.
   PubMed Web of Science ®Google Scholar
• Hamauchi S, Yamazaki K, Masuishi T, et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer. 2017;16(1):51–57.
   PubMed Web of Science ®Google Scholar
• Han Y, Yu Z, Wen S, et al. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat. 2012;131(2):483–490.
   PubMed Web of Science ®Google Scholar
• Huang CS, Liu L, Liu J, et al. Association of chemotherapy-induced leucopenia with treatment outcomes in advanced non-small-cell lung cancer cases receiving the NP regimen. Asian Pac J Cancer Prev. 2012;13(9):4481–4485.
   PubMedGoogle Scholar
• Ishitobi M, Komoike Y, Motomura K, et al. Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology. 2010;78(3-4):213–219.
   PubMed Web of Science ®Google Scholar
• Kasi PM, Kotani D, Cecchini M, et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016;16(1):467.
   PubMedGoogle Scholar
• Kurihara T, Kogo M, Ishii M, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2015;76(6):1217–1224.
   PubMed Web of Science ®Google Scholar
• Lee CK, Gurney H, Brown C, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer. 2011;105(3):360–365.
   PubMed Web of Science ®Google Scholar
• Ma RM, Chen CZ, Zhang W, et al. Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer. Medicine (Baltimore). 2016;95(13):e3240.
   PubMed Web of Science ®Google Scholar
• Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001;91(12):2246–2257.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Agelaki S, Kakolyris S, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer. 2008;62(3):356–363.
   PubMed Web of Science ®Google Scholar
• Paridaens R, Wildiers J, Dumez H, et al., editors. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis. 27th ESMO Congress. 18–22 October; 2002; Nice: Oxford university press.
   Google Scholar
• Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer. 1999;80(11):1763–1766.
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Matthews KS, Kemper MK, et al. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol. 2008;108(2):336–341.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Rissanen P, et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer. 1997;75(2):301–305.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009;45(10):1757–1763.
   PubMed Web of Science ®Google Scholar
• Sunaga T, Suzuki S, Kogo M, et al. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy. Eur J Cancer Care (Engl). 2014;23(3):394–400.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Java JJ, Gatcliffe TA, et al. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol. 2014;133(3):439–445.
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Matsumoto S, Teramukai S, et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer. 2007;97(1):37–42.
   PubMed Web of Science ®Google Scholar
• Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. JCO. 2005;23(31):8003–8011.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa B, Jassem J, Karnicka-Mlodkowska H, et al. Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer? J Cancer Res Clin Oncol. 1998;124(2):106–112.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Park JY, Kim DY, et al. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand. 2010;89(5):623–628.
   PubMed Web of Science ®Google Scholar
• Koutras AK, Hellenic Cooperative Oncology Group, Fountzilas G, Dafni U, et al. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. Anticancer Res. 2008;28(5B):2913–2920.
   PubMed Web of Science ®Google Scholar
• Kumpulainen EJ, Hirvikoski PP, Johansson RT. Neutropenia during adjuvant chemotherapy of breast cancer is not a predictor of outcome. Acta Oncol. 2009;48(8):1204–1206.
   PubMed Web of Science ®Google Scholar
• Smoragiewicz M, Javaheri KR, Yin Y, et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Canc. 2014;45(4):460–465.
   PubMedGoogle Scholar
• Shitara K, Matsuo K, Oze I, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–307.
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205–1211.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Paesmans M, Beauduin M, et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. JCO. 2009;27(5):720–725.
   PubMed Web of Science ®Google Scholar
• French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19(3):602–611.
   PubMed Web of Science ®Google Scholar
• Edlund P, Ahlgren J, Bjerre K, et al. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncol. 2011;50(3):329–337.
   PubMed Web of Science ®Google Scholar
• Lindman H, Andersson M, Ahlgren J, et al. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). Eur J Cancer. 2018;94:79–86.
   PubMed Web of Science ®Google Scholar
• Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40(1):67–71.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. JCO. 2007;25(30):4707–4713.
   PubMed Web of Science ®Google Scholar
• Haslam DW, James WP. Obesity. Obesity. Lancet. 2005;366(9492):1197–1209.
   PubMed Web of Science ®Google Scholar
• Matikas A, Foukakis T, Moebus V, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2019;30(1):109–114.
   PubMed Web of Science ®Google Scholar
• Zielinski C, Lang I, Beslija S, et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer. 2016;114(2):163–170.
   PubMed Web of Science ®Google Scholar
• Donskov F, Michaelson MD, Puzanov I, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015;113(11):1571–1580.
   PubMed Web of Science ®Google Scholar
• Fujita T, Wakatabe Y, Matsumoto K, et al. Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma. Anticancer Res. 2014;34(7):3781–3787.
   PubMed Web of Science ®Google Scholar
• Rautiola J, Donskov F, Peltola K, et al. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int. 2016;117(1):110–117.
   PubMed Web of Science ®Google Scholar
• Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012;21(4):507–513.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–2048.
   PubMed Web of Science ®Google Scholar
• EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440–1452.
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. JCO. 2003;21(2):298–305.
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. JCO. 1999;17(11):3374–3388.
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. JCO. 1997;15(5):1858–1869.
   PubMed Web of Science ®Google Scholar
• Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anticancer Drugs. 2014;25(5):512–521.
   PubMed Web of Science ®Google Scholar
• Foukakis T, for the Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG), von Minckwitz G, Bengtsson NO, et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016;316(18):1888–1896.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Younis T, Rayson D, Jovanovic S, et al. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. Breast Cancer Res Treat. 2016;159(3):425–432.
   PubMed Web of Science ®Google Scholar
• Palmieri C, Jones A. The 2011 EBCTCG polychemotherapy overview. Lancet. 2012;379(9814):390–392.
   PubMed Web of Science ®Google Scholar